SG11202002186VA - Novel artificial nucleic acid molecules - Google Patents

Novel artificial nucleic acid molecules

Info

Publication number
SG11202002186VA
SG11202002186VA SG11202002186VA SG11202002186VA SG11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA
Authority
SG
Singapore
Prior art keywords
nucleic acid
acid molecules
artificial nucleic
novel artificial
novel
Prior art date
Application number
SG11202002186VA
Inventor
Thomas Schlake
Andreas Thess
Moritz Thran
Frédéric Chevessier-Tünnesen
Marion Pönisch
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/057552 external-priority patent/WO2018172556A1/en
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of SG11202002186VA publication Critical patent/SG11202002186VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
SG11202002186VA 2017-10-19 2018-10-17 Novel artificial nucleic acid molecules SG11202002186VA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2017076775 2017-10-19
EP2017076741 2017-10-19
PCT/EP2018/057552 WO2018172556A1 (en) 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof
EP2018076185 2018-09-26
PCT/EP2018/078453 WO2019077001A1 (en) 2017-10-19 2018-10-17 Novel artificial nucleic acid molecules

Publications (1)

Publication Number Publication Date
SG11202002186VA true SG11202002186VA (en) 2020-05-28

Family

ID=66173912

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002186VA SG11202002186VA (en) 2017-10-19 2018-10-17 Novel artificial nucleic acid molecules

Country Status (13)

Country Link
US (1) US20220233568A1 (en)
EP (1) EP3697912A1 (en)
JP (2) JP2021501572A (en)
KR (1) KR20200071081A (en)
CN (1) CN111630173A (en)
AU (1) AU2018351481A1 (en)
BR (1) BR112020004351A2 (en)
CA (1) CA3073634A1 (en)
IL (1) IL272850A (en)
MX (1) MX2020003995A (en)
RU (1) RU2020115287A (en)
SG (1) SG11202002186VA (en)
WO (1) WO2019077001A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
EP3601576A1 (en) 2017-03-24 2020-02-05 CureVac AG Nucleic acids encoding crispr-associated proteins and uses thereof
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
RU2020117848A (en) 2017-11-08 2021-12-08 Куревак Аг PHK SEQUENCE ADAPTATION
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
JP2021519595A (en) * 2018-04-17 2021-08-12 キュアバック アーゲー New RSV RNA molecule and vaccination composition
CN110241116B (en) * 2019-05-21 2023-02-07 中国医学科学院放射医学研究所 Circular RNA and application thereof in promoting DNA damage repair
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
BR112022001947A2 (en) 2019-08-14 2022-09-20 Curevac Ag RNA COMBINATIONS AND COMPOSITIONS WITH REDUCED IMMUNOSTIMULATORY PROPERTIES
JP2022546417A (en) * 2019-08-29 2022-11-04 チューリッヒ大学 Minimal mRNA and its uses
CN110592223B (en) * 2019-10-31 2022-10-25 中南大学湘雅三医院 Application of diagnostic and prognostic marker hsa _ circRNA _012515 for NSCLC
CN112759652B (en) * 2019-11-01 2022-09-20 北京华夏清医治疗科技有限公司 Chimeric antigen receptor and application thereof
US20230008266A1 (en) * 2019-11-07 2023-01-12 Icahn School Of Medicine At Mount Sinai Synthetic modified rna and uses thereof
CN111041025B (en) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 mRNA targeting molecule based on combination of N-acetylgalactosamine polypeptide and preparation method thereof
MX2022007680A (en) 2019-12-20 2022-09-26 Curevac Ag Lipid nanoparticles for delivery of nucleic acids.
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
IL293571A (en) 2020-02-04 2022-08-01 Curevac Ag Coronavirus vaccine
US20230096704A1 (en) * 2020-02-05 2023-03-30 University Of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
AU2021247163A1 (en) * 2020-04-01 2022-10-20 University Of Florida Research Foundation, Incorporated Multilamellar RNA nanoparticle vaccine against SARS-CoV-2
CN111413498B (en) * 2020-04-08 2023-08-04 复旦大学附属中山医院 Autoantibody 7-AAb detection panel for liver cell liver cancer and application thereof
KR20230053008A (en) 2020-05-29 2023-04-20 큐어백 에스이 Nucleic Acid-Based Combination Vaccines
CN111744019B (en) * 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 Mannose-based mRNA targeted delivery system and application thereof
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
CN116157525A (en) * 2020-08-07 2023-05-23 香港科技大学 Compositions and methods for increasing protein expression
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
WO2022076901A1 (en) * 2020-10-09 2022-04-14 Duke University Novel targets for reactivation of prader-willi syndrome-associated genes
CN112280750B (en) * 2020-10-22 2022-11-01 山东农业大学 Novel goose astrovirus with cross-species transmission capability and application thereof
CN112526127B (en) * 2020-10-28 2022-12-06 四川大学华西医院 Detection method of tetanus antigen and application thereof
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
CN112574997B (en) * 2021-01-17 2023-07-21 楷拓生物科技(苏州)有限公司 Modified body of FBXW7 annular RNA and application of modified body in tumor medicaments and novel crown vaccines
EP4087938A2 (en) 2021-01-27 2022-11-16 CureVac AG Method of reducing the immunostimulatory properties of in vitro transcribed rna
JP2024508707A (en) * 2021-02-12 2024-02-28 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） Activity-inducing fusion protein with heat shock protein 90 binding domain
EP4313152A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
CN113341152B (en) * 2021-04-27 2022-04-26 华南农业大学 Application of RPS9 protein in prediction of good response of crab eating monkey to superovulation
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
CA3171750A1 (en) 2021-07-30 2023-02-02 Tim SONNTAG Mrnas for treatment or prophylaxis of liver diseases
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
CA3230056A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
CN115606550B (en) * 2022-10-28 2024-01-12 陆华 Construction method of autoimmune thyroiditis induced ovarian reserve hypofunction animal model
CN116240175B (en) * 2023-02-28 2024-02-23 武汉科技大学 Preparation method of chimeric anti-HIV broad-spectrum neutralizing antibody exosome and application thereof in anti-HIV infection

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102286077A (en) 1996-06-14 2011-12-21 明治乳业株式会社 T-cell epitope peptides
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
EP1246597B1 (en) 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
EP1800697B1 (en) 2001-06-05 2010-04-14 CureVac GmbH Stabilised mRNA with increased G/C-content for use in gene therapy
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
ES2601432T3 (en) 2006-08-11 2017-02-15 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
EP2176408B9 (en) 2008-01-31 2015-11-11 Curevac GmbH NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
KR101734955B1 (en) 2008-11-07 2017-05-12 메사추세츠 인스티튜트 오브 테크놀로지 Aminoalcohol lipidoids and uses thereof
CA3039251C (en) 2008-11-10 2024-01-09 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010087791A1 (en) 2009-01-27 2010-08-05 Utc Power Corporation Distributively cooled, integrated water-gas shift reactor and vaporizer
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CN102421417B (en) 2009-05-05 2016-03-02 阿尔尼拉姆医药品有限公司 Lipid composition
EP2440183B1 (en) 2009-06-10 2018-07-18 Arbutus Biopharma Corporation Improved lipid formulation
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2555752B1 (en) 2010-04-09 2019-06-26 Pacira Pharmaceuticals, Inc. Method for formulating multivesicular liposomes
JP5893611B2 (en) 2010-06-03 2016-03-23 アルニラム・ファーマシューティカルズ・インコーポレーテッド Biodegradable lipids for delivery of active agents
MX343410B (en) 2010-07-06 2016-11-04 Novartis Ag * Cationic oil-in-water emulsions.
ES2557382T3 (en) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomes with lipids that have an advantageous pKa value for RNA delivery
ES2558106T3 (en) 2010-07-30 2016-02-02 Curevac Ag Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
HUE058361T2 (en) 2010-08-31 2022-07-28 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
FI4043040T3 (en) 2010-08-31 2023-04-04 Glaxosmithkline Biologicals Sa Small liposomes for delivery of immunogen-encoding rna
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2013006825A1 (en) 2011-07-06 2013-01-10 Novartis Ag Liposomes having useful n:p ratio for delivery of rna molecules
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
ES2654205T3 (en) * 2012-03-27 2018-02-12 Curevac Ag Artificial nucleic acid molecules for enhanced protein or peptide expression
CA2866945C (en) * 2012-03-27 2021-05-04 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
SG10201801431TA (en) 2013-08-21 2018-04-27 Curevac Ag Respiratory syncytial virus (rsv) vaccine
CN105530952A (en) 2013-08-21 2016-04-27 库瑞瓦格股份公司 Composition and vaccine for treating lung cancer
CA2915712A1 (en) 2013-08-21 2015-02-26 Margit SCHNEE Rabies vaccine
BR112016000889A2 (en) 2013-08-21 2017-12-12 Curevac Ag composition and vaccine for prostate cancer treatment
RU2717986C2 (en) * 2013-12-30 2020-03-27 Куревак Аг Artificial molecules of nucleic acid
ES2754239T3 (en) 2014-03-12 2020-04-16 Curevac Ag Combination of vaccination and OX40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
CA2962849A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
SG11201704681QA (en) * 2014-12-30 2017-07-28 Curevac Ag Artificial nucleic acid molecules
CA2975333A1 (en) 2015-04-22 2016-10-27 Curevac Ag Rna containing composition for treatment of tumor diseases
WO2017001058A1 (en) * 2015-07-01 2017-01-05 Curevac Ag Method for analysis of an rna molecule
BR112018001995A2 (en) * 2015-08-28 2018-09-18 Curevac Ag artificial nucleic acid molecules
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
US20180312545A1 (en) 2015-11-09 2018-11-01 Curevac Ag Optimized nucleic acid molecules
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
WO2018104540A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
EP3601576A1 (en) * 2017-03-24 2020-02-05 CureVac AG Nucleic acids encoding crispr-associated proteins and uses thereof

Also Published As

Publication number Publication date
BR112020004351A2 (en) 2020-09-08
CN111630173A (en) 2020-09-04
JP2021501572A (en) 2021-01-21
IL272850A (en) 2020-04-30
US20220233568A1 (en) 2022-07-28
RU2020115287A3 (en) 2022-02-28
EP3697912A1 (en) 2020-08-26
CA3073634A1 (en) 2019-04-25
MX2020003995A (en) 2020-07-22
KR20200071081A (en) 2020-06-18
JP2024012523A (en) 2024-01-30
RU2020115287A (en) 2021-11-19
AU2018351481A1 (en) 2020-03-12
WO2019077001A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
IL272850A (en) Novel artificial nucleic acid molecules
SG11201911430PA (en) Novel nucleic acid molecules
SG10201913629VA (en) Artificial nucleic acid molecules
SG11201704681QA (en) Artificial nucleic acid molecules
IL278000B (en) Synthetic nucleic acid spike-ins
PL4023755T3 (en) Artificial nucleic acid molecules for improved protein expression
EP3472359A4 (en) Nucleic acid sequencing
IL272463A (en) Nucleic acid molecules and uses thereof
IL254000A0 (en) Nucleic acid sequence assembly
EP3157573A4 (en) Alternative nucleic acid molecules and uses thereof
EP3157572A4 (en) Alternative nucleic acid molecules and uses thereof
SG11201603144QA (en) Artificial nucleic acid molecules
SG11201610168YA (en) Nucleic acid synthesis techniques
HK1243958A1 (en) Nucleic acid construct
EP3118311A4 (en) Antisense nucleic acid
GB201507119D0 (en) Nucleic Acid Construct
HK1244021A1 (en) Nucleic acid construct
GB201507115D0 (en) Nucleic Acid Construct
LT3094731T (en) Saccharide-modified nucleic acid molecules
GB201507111D0 (en) Nucleic acid construct
IL277472A (en) Nucleic acid molecules for pseudouridylation
ZA202001649B (en) Rna molecules
GB201812474D0 (en) Nucleic acid construct
GB201617548D0 (en) Novel biological factor
EP3351251A4 (en) Nucleic acid molecule